DiamiR Biosciences Corp.
private/Aptorum Group LimitedAPMAptorum Group to Merge with DiamiR Biosciences; Combined Company to Be Niki BioSolutions
Key takeaways
- Expected close: Jun 30, 2026.
Deal value
—
stock
Per-share offer
—
Premium
—
Days to close
17d overdue
Jun 30, 2026
Term fee
—
Announced
Apr 24, 2026
Preliminary Proxy
—
Definitive Proxy
—
Record date
—
Shareholder vote
—
Expected close
Jun 30, 2026
No regulatory or closing-conditions data extracted yet. The merger agreement Exhibit 10.1 contains this in the “Conditions to Closing” and “Regulatory Approvals” articles.
No closing-condition data extracted.
No competing-bidder, activist, or dissident-proxy signals in the database for this target.
Acquirer side· Aptorum Group Limited
Legal
Hunter Taubman Fischer & Li LLC
- · Louis Taubman
“Copies of all communications, including communications sent to agent for service, should be sent to: Louis Taubman, Esq. Hunter Taubman Fischer & Li LLC 950 Third Avenue, 19th Floor New York, NY 10022”
Ellenoff Grossman & Schole LLP
- · Jonathan Deblinger
- · John J. Hart
“Jonathan Deblinger, Esq. John J. Hart, Esq. Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas New York, NY 10105-0302”
Target side· DiamiR Biosciences Corp.
None on record
| Firm | Role | Side | Deals in DB | |
|---|---|---|---|---|
| Ellenoff Grossman & Schole LLP | Legal | Acquirer | 8 | View deals → |
| Hunter Taubman Fischer & Li LLC | Legal | Acquirer | 1 | View deals → |
- Jul 16, 2026today
Aptorum Group Closes DiamiR Merger, Rebrands as Niki BioSolutions
- Apr 24, 2026this filing
Aptorum Group to Merge with DiamiR Biosciences; Combined Company to Be Niki BioSolutions
| Date | Form | Section | Headline | Status |
|---|---|---|---|---|
| Jul 16, 2026 | — | definitive | Aptorum Group Closes DiamiR Merger, Rebrands as Niki BioSolutions | post_vote |
Aptorum Group Limited, a Cayman Islands company, agreed to merge with DiamiR Biosciences Corp., a Delaware corporation, with DiamiR surviving as a wholly owned subsidiary of Aptorum. Upon closing, DiamiR shareholders will own approximately 70% of the combined company's common stock, while existing Aptorum shareholders will own approximately 30%. The combined company will be renamed Niki BioSolutions, Inc. and is expected to trade on Nasdaq under the symbol NIKI.